^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FOLH1 expression

    i
    Other names: FOLH1, FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA, Folate hydrolase 1, prostate-specific membrane antigen
    Entrez ID:
    2346
    Related biomarkers:
    Expression
    Apply
    A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients with Prostate Cancer (OncoACP-3) (NCT06840535)
    Phase 1
    Philogen S.p.A.
    Not yet recruiting
    Last update posted :
    02/21/2025
    Initiation :
    02/01/2025
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    FOLH1
    |
    FOLH1 expression
    Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer (NCT06827080)
    Phase 1/2
    Zhengguo Chen
    Not yet recruiting
    Last update posted :
    02/14/2025
    Initiation :
    02/11/2025
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    FOLH1
    |
    FOLH1 expression
    68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients (NCT05324332)
    Phase N/A
    Peking Union Medical College Hospital
    Recruiting
    Last update posted :
    11/27/2024
    Initiation :
    04/15/2022
    Primary completion :
    01/01/2025
    Completion :
    01/31/2025
    FOLH1
    |
    FOLH1 expression
    An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients with Metastatic Adenoid Cystic Carcinoma (NCT06521775)
    Phase 2
    Mayo Clinic
    Enrolling by invitation
    Last update posted :
    09/23/2024
    Initiation :
    08/12/2024
    Primary completion :
    08/12/2025
    Completion :
    08/12/2025
    FOLH1
    |
    FOLH1 expression
    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer (NCT04573231)
    Phase 2
    University of Wisconsin, Madison
    Recruiting
    Last update posted :
    05/22/2024
    Initiation :
    05/24/2021
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    HER-2 • FOLH1
    |
    HER-2 negative • AR expression • FOLH1 expression
    ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer (APEX-01) (NCT04662580)
    Phase 1
    Ambrx, Inc.
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    07/27/2021
    Primary completion :
    12/01/2025
    Completion :
    03/01/2027
    FOLH1
    |
    FOLH1 expression
    |
    Xtandi (enzalutamide) • JNJ-8177
    CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer (NCT03089203)
    Phase 1
    University of Pennsylvania
    Active, not recruiting
    Last update posted :
    04/26/2024
    Initiation :
    03/08/2017
    Primary completion :
    09/08/2038
    Completion :
    12/08/2038
    TGFB1
    |
    FOLH1 expression
    |
    cyclophosphamide • fludarabine IV • CART-PSMA- TGFβRDN cells
    PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer (NCT04310540)
    Phase 1
    Mayo Clinic
    Completed
    Last update posted :
    04/11/2024
    Initiation :
    06/05/2020
    Primary completion :
    11/02/2023
    Completion :
    11/02/2023
    FOLH1
    |
    FOLH1 expression
    NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial (NCT06066437)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    04/01/2024
    Initiation :
    03/29/2024
    Primary completion :
    06/30/2025
    Completion :
    06/30/2026
    FOLH1
    |
    FOLH1 expression
    |
    Firmagon (degarelix)
    A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors (NCT03972657)
    Phase 1/2
    Regeneron Pharmaceuticals
    Recruiting
    Last update posted :
    03/08/2024
    Initiation :
    08/12/2019
    Primary completion :
    08/01/2025
    Completion :
    07/03/2026
    FOLH1
    |
    FOLH1 expression
    |
    Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab) • nezastomig (REGN5678)
    68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer (NCT04762888)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    01/18/2024
    Initiation :
    02/24/2021
    Primary completion :
    01/10/2025
    Completion :
    07/07/2025
    FOLH1
    |
    FOLH1 expression • FOLH1 overexpression
    Role of F-18 PSMA in Prostate Cancer Patient (NCT06209853)
    Phase N/A
    Assiut University
    Not yet recruiting
    Last update posted :
    01/18/2024
    Initiation :
    01/15/2024
    Primary completion :
    03/01/2025
    Completion :
    04/01/2025
    FOLH1
    |
    FOLH1 expression